of hypertension. avapro for hypertension may also delay progression of diabetic nephropathy avapro for hypertension is also indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations.

hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM avapro for hypertension ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was avapro for hypertension by Sanofi Research (now part of sanofi-aventis). It is avapro for hypertension marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with avapro for hypertension avapro for hypertension See also[edit] Clinical useMain article: avapro for hypertension II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now avapro for hypertension of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl Clarke.

[hide]1 Clinical use1.1 Indications1.2 Combination with diureticIrbesartan is also available in a combination.